1. A 50-year-old male was recently diagnosed with Ph-positive acute lymphoblast leukemia. Which of the following options is preferred as the initial induction treatment regimen?

2. A 35-year-old male was previously treated with chemotherapy plus tyrosine kinase inhibitor (TKI) followed by an allogeneic hematopoietic cell transplant (HCT) for Ph-positive acute lymphoblastic leukemia. He now has experienced disease relapse while on TKI maintenance therapy. Which treatment option is preferred at this stage of disease management?

3. A 25-year-old female was diagnosed with Ph-negative acute lymphoblastic leukemia. She completed hyper-CVAD induction treatment. She achieved a complete response and her minimal residual disease assessment was positive. Which of the following treatments should be used as her consolidation therapy?

4. A patient has completed induction therapy; the minimal residual disease assessment determines that he achieved complete remission. Treatment continues with consolidation therapy and then maintenance therapy. During maintenance therapy, the patient will receive intrathecal therapy along with methotrexate and mercaptopurine. Thiopurine S-methyltransferase (TPMT) testing is completed, and the patient is identified as having intermediate TPMT activity. How should mercaptopurine be initiated in this patient?

5. A patient with acute lymphoblastic leukemia is scheduled to start consolidation therapy with high-dose methotrexate. Which of the following medications is safe to use during chemotherapy and would not put the patient at risk for a known drug-drug interaction or excess toxicity?

6. Research in the setting of acute lymphoblastic leukemia (ALL) treatment is focusing on numerous immunotherapy targets, including CD20-targeting agents. Which of the following statements is correct regarding ongoing ALL research trials related to CD20?

7. An effective strategy to mitigate side effects related to treatment for acute lymphoblastic leukemia is to:

8. Pharmacists can facilitate medication adherence by:

9. Which of the following adverse effects is NOT associated with blinatumomab?

10. Which of the following is TRUE about the use of different formulations of L-asparaginase used to treat acute lymphoblastic leukemia?

« Return to Activity